Online citations, reference lists, and bibliographies.

Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Intraoperative Chemotherapy In The Treatment Of Advanced Epithelial Ovarian Cancer

A. Tentes, S. Kakolyris, D. Kyziridis, C. Karamveri
Published 2012 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Background/Aims. Intraperitoneal intraoperative hyperthermic chemotherapy (HIPEC) has been used in the treatment of ovarian cancer. The purpose of the study is to determine the efficacy of HIPEC after cytoreductive surgery in advanced ovarian cancer. Patients/Methods. From 2006 to 2010 patients with advanced ovarian cancer were enrolled in a prospective nonrandomized study to undergo cytoreductive surgery combined with HIPEC. Clinical and histopathological variables were correlated to hospital mortality, morbidity, survival, and recurrences. Results. The mean age of 43 women was 59.9 ± 13.8 (16–82) years. The hospital mortality and morbidity rate were 4.7% and 51.2%, respectively. Complete cytoreduction was possible in 69.8%. The overall 5-year survival rate was 54%. The prognostic indicators of survival were the extent of prior surgery (P = 0.048) and the extent of peritoneal dissemination (P = 0.011). The recurrence rate was 30.2%. Conclusions. Maximal cytoreductive surgery combined with HIPEC is a well-tolerated, feasible, and promising method of treatment in advanced ovarian cancer.
This paper references
Cytore - ductive surgery ( peritonectomy procedures ) combined with hyperthermic intraperitoneal chemotherapy ( HIPEC ) in the treatment of di ff use peritoneal carcinomatosis from ovarian
C. R. Rossi (2008)
Management of Peritoneal Surface Malignancy Using Inytraperitoneal Chemotherapy and Cytoreductive Surgery. A Manual for Physicians and Nurses
P H Sugarbaker (1998)
10.1038/sj.bjc.6601586
Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study
H. Mahteme (2004)
10.1007/0-387-33863-2_14
Total Abdominal Colectomy
H. Kessler (2006)
10.1002/JSO.20013
Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy.
V. Verwaal (2004)
10.1097/01.sla.0000231705.40081.1a
Survival Analysis of Pseudomyxoma Peritonei Patients Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
R. M. Smeenk (2007)
10.3748/WJG.14.1159
Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis.
Hassan-Alaa-Hammed Al-Shammaa (2008)
10.1102/1470-7330.2007.0030
Cytoreductive surgery in ovarian cancer
C. Pomel (2007)
10.1002/bjs.1800780742
Influence of local hyperthermia on the healing of small intestinal anastomoses in the rat
A. M. Kappas (1991)
Management of Peritoneal Surface Malignancy Using Inytraperitoneal Chemotherapy and Cytoreductive Surgery. A Manual for Physicians and Nurses, Ludann Company
P H Sugarbaker (1998)
10.1097/00000658-199501000-00004
Peritonectomy Procedures
P. Sugarbaker (2003)
10.1186/1477-7819-2-21
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer
P. Piso (2004)
10.1007/s004230050246
Management of peritoneal-surface malignancy: the surgeon’s role
P. Sugarbaker (1999)
10.1002/cncr.21708
Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion
S. Kusamura (2006)
10.1056/NEJM199601043340101
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.
W. Mcguire (1996)
10.1177/030089160108700302
Cytoreductive Surgery Followed by Intraperitoneal Hyperthermic Perfusion in the Treatment of Recurrent Epithelial Ovarian Cancer: A Phase II Clinical Study
M. Deraco (2001)
Secondary cytoreductive surgery for ovarian cancer.
T. Burke (1994)
10.1002/JSO.20161
Intraperitoneal heated chemotherapy affects healing of experimental colonic anastomosis: an animal study.
V. Makrin (2005)
10.1200/JCO.20.5.1248
Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.
R. Bristow (2002)
10.1007/s00268-007-9146-8
Cytoreductive Surgery and Intraperitoneal Chemohyperthermia for Chemoresistant and Recurrent Advanced Epithelial Ovarian Cancer: Prospective Study of 81 Patients
E. Cotte (2007)
Cytoreductive surgery and intraperitoneal chemohyperthermia for chemoresistant and recurrent advanced epithelial ovarian cancer: prospective 6 Journal of Oncology study of 81 patients
E. Cotte (1813)
10.1002/cncr.23553
Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer
A. di Giorgio (2008)
Cancer of the ovary.
M. McKay (1994)
10.1245/s10434-006-9169-7
Prognostic Indicators for Patients Undergoing Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Diffuse Malignant Peritoneal Mesothelioma†
T. Yan (2006)
10.1007/s00268-004-7461-x
Cytoreductive Surgery and Intraperitoneal Chemohyperthermia for Recurrent Peritoneal Carcinomatosis from Ovarian Cancer
C. Zanon (2004)
10.1200/jco.1996.14.6.1895
Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group.
M. Bookman (1996)
10.1111/J.1525-1438.2006.00580.X
Long‐term survival in advanced ovarian carcinoma following cytoreductive surgery with standard peritonectomy procedures
A. Tentes (2006)
10.1056/NEJMOA052985
Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
D. Armstrong (2006)
10.1111/J.1525-1438.2003.13319.X
Long‐term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum
M. Look (2003)
10.1002/JSO.10270
Total abdominal colectomy, pelvic peritonectomy, and end-ileostomy for the surgical palliation of mucinous peritoneal carcinomatosis from non-gynecologic cancer.
K. Stamou (2003)
Management of Peritoneal Surface Malignancy Using Inytraperitoneal Chemotherapy and Cytoreductive Surgery. A Manual for Physicians and Nurses, Ludann
P. H. Sugarbaker (1998)
10.1002/JSO.20597
Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer.
S. Rufián (2006)
10.1002/cncr.20192
Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis
C. Rossi (2004)



This paper is referenced by
10.5430/CSS.V2N1P27
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer
John Spiliotis (2015)
10.1016/j.tranon.2016.02.002
Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy to Treat Advanced/Recurrent Epithelial Ovarian Cancer: Results from a Retrospective Study on Prospectively Established Database1
J. Sun (2016)
10.1016/j.ejogrb.2014.05.018
Cytoreduction and HIPEC after neoadjuvant chemotherapy in stage IIIC-IV ovarian cancer. Critical analysis in elderly patients.
P. Cascales-Campos (2014)
10.2217/EBO.13.602
The use of heated intraperitoneal chemotherapy for the treatment of gynecologic carcinomatosis
Sarah K Goodrich (2014)
10.1007/s13193-018-0782-2
Cytoreductive Surgery in Combination with HIPEC in the Treatment of Peritoneal Sarcomatosis
C. Karamveri (2018)
10.3978/j.issn.2078-6891.2015.111
Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy.
Martin D. Goodman (2016)
Cytoreduction and HIPEC for peritoneal carcinomatosis of pancreatic cancer.
A. Tentes (2018)
10.5200/SM-HS.2013.079
Experience of Hipec and Cytoreductive Surgery in Klaipeda University Hospital
Vitalijus Eismontas (2013)
10.1007/s00404-014-3153-4
Security and efficiency of a closed-system, turbulent-flow circuit for hyperthermic intraperitoneal chemotherapy after cytoreductive ovarian surgery: perioperative outputs
Javier Pascual-Ramírez (2014)
10.9738/INTSURG-D-14-00138.1
Hemodynamic Monitoring During Heated Intraoperative Intraperitoneal Chemotherapy Using the FloTrac/Vigileo System.
Christos Mavroudis (2015)
10.15557/CGO.2013.0003
Wstępna ocena przydatności dootrzewnowej perfuzyjnej chemioterapii w warunkach hipertermii (HIPEC) u chorych z nowotworowym rozsiewem wewnątrzotrzewnowym
Beata Śpiewankiewicz (2013)
10.1007/s11864-013-0264-2
Intraperitoneal Chemotherapy from Armstrong to HIPEC: Challenges and Promise
Ramez N. Eskander (2013)
10.3892/OL.2019.10493
Ascites do not affect the rate of complete cytoreductive surgery and prognosis in patients with primary ovarian cancer with ascites treated with hyperthermic intraperitoneal chemotherapy.
Mingchen Ba (2019)
10.1016/j.ygyno.2014.11.072
A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer.
L. Chiva (2015)
10.1016/j.suronc.2014.03.004
Intraperitoneal chemotherapy against peritoneal carcinomatosis: current status and future perspective.
Joji Kitayama (2014)
10.4172/2161-1076.1000125
Current Indications, Techniques and Results of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Intra-Abdominal Malignancies
Meagan Wademan (2012)
Management of peritoneal surface malignancy: a review of the recent literature.
E. Halkia (2014)
10.5200/sm-hs.2013.079
HIPEC IR CITOREDUKCINIŲ OPERACIJŲ PATIRTIS
V. Eismontas (2013)
10.1007/s00280-017-3376-8
Consolidation hyperthermic intraperitoneal chemotherapy for the treatment of advanced stage ovarian carcinoma: a 3 year experience
A. Mendivil (2017)
10.1007/s40944-018-0218-5
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) as Primary Treatment of Ovarian Cancer: A Review of the Current Literature
Samira Zirak-Schmidt (2018)
10.6004/JNCCN.2013.0142
Ovarian cancer, version 2.2013: Featured updates to the NCCN guidelines
R. Morgan (2013)
The cost of cytoreductive surgery and perioperative intraperitoneal chemotherapy in the treatment of peritoneal malignancy in one Greek institute.
A. Tentes (2012)
Place des résections pelviennes élargies associées à une chimiothérapie hyperthermique intra-péritonéale dans le traitement de la carcinose péritonéale
Julien Coget (2013)
10.5317/WJOG.V2.I4.94
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in epithelial ovarian cancer: State of the art
Ramez N. Eskander (2013)
10.2147/CMAR.S31070
Intraperitoneal chemotherapy in ovarian cancer: a review of tolerance and efficacy
D. L. Chan (2012)
10.1016/j.ejso.2015.08.172
Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: A systematic review and meta-analysis.
Y. R. Huo (2015)
10.15557/CGO.2014.0009
Zasady stosowania dootrzewnowej chemioterapii w hipertermii (HIPEC) w leczeniu nowotworów złośliwych powierzchni otrzewnej w połączeniu z zabiegami cytoredukcyjnymi: zalecenia krajowe Polish clinical practice guideline on Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Cytoreductice Surgery (
Piotr Rutkowski (2014)
10.1080/14656566.2020.1766024
An overview and update of hyperthermic intraperitoneal chemotherapy in ovarian cancer
Eelco de Bree (2020)
10.1097/IGC.0000000000000327
Prognostic Significance of Sugarbaker’s Peritoneal Cancer Index for the Operability of Ovarian Carcinoma
Bjoern Lampe (2015)
The role of cytoreductive surgery in advanced ovarian cancer: the general surgeon's perspective.
K. Romanidis (2014)
10.4238/gmr16019411
Long non-coding RNA ENST00000457645 reverses cisplatin resistance in CP70 ovarian cancer cells.
H. Yan (2017)
10.3109/02656736.2015.1075606
Lack of significant intraoperative coagulopathy in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) indicates that epidural anaesthesia is a safe option
O. Korakianitis (2015)
See more
Semantic Scholar Logo Some data provided by SemanticScholar